Students marched on Trousdale Parkway Wednesday afternoon to advocate for the installation of solar panels on USC roofs as part of a protest organized by the USC Go Solar Campaign, a branch of the Environmental Core.Connor Mitchell, a freshman majoring in business administration, said the University has a unique opportunity to reduce its carbon footprint of because of Los Angeles’s commonly sunny weather.“USC should adopt solar because we have days like this all year long, and there is this energy out there that can power our planet,” Mitchell said.The protest began at the Annenberg Amphitheater as dozens of students convened to distribute posters emblazoned with slogans like “USC is Bright, Let’s Use the Light” and “Why Aren’t We Using Our Roofs.” Environmental Core co-directors Ethan Bialick and Zach Manta gave brief speeches detailing the group’s efforts to bring solar panels to the University, as well as the goals of the protest.“Today we’re coming here with a proposal that literally says this company will pay USC to put solar on these roofs,” Bialick said. “We’re bringing this to them, and we’re going to protest that they need to do this now [and] they need to make a commitment now.”Demonstrators then marched down Trousdale Parkway, before circling in front of Tommy Trojan. Students, led by Manta, chanted slogans such as “This is the hour for solar power” and “Solar makes sense.” Afterward, students shared their own reasons for why they thought solar power was a top priority for USC.“I support USC switching to solar because, as a world-class University at a time when renewable is readily available, there is no reason why we should be relying on dirty fossil fuels,” said Olivia Pearson, a freshman majoring in environmental engineering.After the protest, the Environmental Core presented administration officials with a proposal from the energy company SolarCity to lease USC’s unused rooftops to install solar panels owned and maintained by the company. The University will only need to host the panels and collect the lease payments from Solar City, which will alleviate the financial burden of the solar panels.“We’ve repeatedly been told by administrators that they’re not willing to put the money down and invest in solar systems because the payback period is too long for their high-risk, high-reward financial strategies,” Manta said. “Although solar does financially make sense, we want to be very clear that this is not primarily a financial decision.”Bialick hopes that the protest will show the University’s administration that installing solar panels is both socially responsible and financially feasible.“Ideally, they would recognize that they have a sustainability plan that says they’ll procure renewable energy when economic, and this [proposal] literally pays them to get renewable energy,” Bialick said. “If they refuse this, they’re essentially breaking from what they said.”
Fans of the North London club predictably took to social media to take on the Black Stars gaffer after he made those comments, asking why the Black Stars were chasing Gunners youngster Eddie Nketiah to represent Ghana, if Akonnor didn’t think Arsenal was good enough.Some went further to accuse C.K Akonnor, who once captained German Bundesliga side, Wolfsburg and the Black Stars, of jealousy.Others, however, commended the coach for his forthrightness on the matter.Take a look at some of the reactions below: Arsenal fans weren’t too happy with Black Stars head coach, Charles Kwablan Akonnor’s advice to midfielder Thomas Partey not to move to the Premier League club.Speaking on Starr FM on Wednesday night, Akonnor suggested that staying at Atletico Madrid might be the best thing for Partey, as he would be guaranteed Champions League football, unlike at Arsenal.“Honestly, I wouldn’t want him to move to Arsenal because, with Atletico, he will always play Champions League football. His position is guaranteed and he will always play. With Arsenal, I’m not too sure,” Akonnor said.“I’m sure money issues will come in, but I hope that whatever he asks for, Atletico will be able to pay.”Akonnor, who knew that his comments would not go down well with Gunners fans, remarking: “Arsenal fans will kill me.”Thomas ParteyAnd that has indeed proven to be the case.Arsenal have been pursuing a deal for the Ghanaian midfielder since January.The English club are reluctant to pay Partey’s €50m release clause and recently had an offer of £23m plus Matteo Guendouzi rejected by Atletico.More from Citi Sports
The Good News And The Bad News: Drugs May Offer Relief To Migraine Sufferers, But They Come At High Cost An analysis finds that the new medications, which could carry a $8,500 price tag, are not cost effective. In other pharmaceutical news, a gene therapy trial for Duchenne muscular dystrophy has begun, and an online pharmacy is fined for importing counterfeit cancer drugs. The Associated Press: Canadian Pharmacy To Be Fined Millions For Illegal Imports A pair of long-acting drugs that would be the first used for preventing migraines may cause a different kind of headache. Known as CGRP inhibitors, the injectable drugs work by interfering with a substance involved in modifying nerve signals, and recent studies found that two of the medicines reduce the frequency at which migraines appeared. This may be good news for the estimated 38 million migraine sufferers in the U.S., as well as investors, since the market for such drugs will be worth billions of dollars. (Silverman, 4/12) An online pharmacy that bills itself as Canada’s largest is expected to be fined $34 million Friday for importing counterfeit cancer drugs and other unapproved pharmaceuticals into the United States, a sentence that one advocacy group called too light for such a heinous crime. Canada Drugs has filled millions of prescriptions by offering itself as a safe alternative for patients to save money on expensive drugs, and its founder, Kristian Thorkelson, has been hailed as an industry pioneer for starting the company in 2001. (Volz, 4/13) Stat: Pfizer Latest To Test Gene Therapy For Duchenne Muscular Dystrophy Stat: New Migraine Drugs May Give Insurers A Headache Pfizer (PFE) has begun its first human trials of a gene therapy to treat Duchenne muscular dystrophy, following two other companies that have launched trials and one treatment for the disease in recent years. The first patient received the experimental therapy, called PF-06939926, on March 22, Pfizer said Thursday. The study is expected to run through 2019 and to enroll about a dozen boys from 5 to 12 years old at four sites. (Cooney, 4/12) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.